

Max Mitteregger resigns from the LIDDS's board

UPPSALA, SWEDEN - LIDDS announces today that Max Mitteregger is leaving the company's board at his own request.

LIDDS announces today that Max Mitteregger will leave the board of directors of LIDDS. The company's board thus consists of Pontus Ottosson (chairman), David Bejker, Daniel Lifveredson and Johan Lund. Max Mitteregger's resignation is at his own request.

"I want to thank Max for the much-appreciated efforts he has made for LIDDS over the past year. I want to emphasize that there is no conflict between the company and Max Mitteregger, but that it is a matter of prioritizing time and resources on the part of both parties. Max will not sell his shares in connection with his leaving his board, but will remain as a shareholder until further notice." says Pontus Ottosson, chairman of the board.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS's Certified Adviser is Redeye AB

This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-02 22:40 CEST.

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

Max Mitteregger resigns from the LIDDS's board